First human test of new pill targets 'Undruggable' cancer mutation
NCT ID NCT06599502
Summary
This early-stage study tested a new oral drug, AZD0022, alone and combined with another cancer drug, in people with advanced solid tumors driven by a specific genetic change called KRASG12D. The main goals were to find a safe dose and see if the treatment caused any side effects. The study was terminated early after enrolling 17 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
New York, New York, 10016, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Seoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.